VARIZIG®

Varicella Zoster Immune Globulin (Human) Intramuscular [Standardized amount of VZV antibody]

Presentation:

1.2 mL single-dose vial of ≥125 IU (≥104 IU/mL)

Therapeutic Indication:

Prevention or reduction in severity of maternal infections within 4 days of exposure to the varicella zoster virus. Administration of VariZIG is recommended for prevention or reduction of severity of maternal infections within 4 days of exposure to the varicella zoster virus. Greatest effectiveness of treatment is expected when it is begun within 4 days of exposure; treatment after 4 days is of uncertain value. Pregnant women may be at a higher risk of complications from chickenpox than healthy adults. The decision to administer VariZIG to a pregnant woman should be evaluated on an individual basis. The clinician should consider the patient’s health status, type of exposure, and likelihood of previous unrecognized varicella infections before deciding whether to administer VariZIG. If, after careful evaluation of all available information, which may include the use of reliable and sensitive tests for varicella antibody, a normal pregnant woman with significant exposure to varicella is believed susceptible, VariZIG may be administered.